(Q37619315)

21 August 2017

1 reference

title

Physiologically-based PK/PD modelling of therapeutic macromolecules (English)

1 reference

21 August 2017

1 reference

Peter Thygesen

1

1 reference

21 August 2017

Panos Macheras

series ordinal

2

1 reference

21 August 2017

Achiel Van Peer

series ordinal

3

1 reference

21 August 2017

publication date

22 October 2009

1 reference

21 August 2017

published in

Pharmaceutical Research

1 reference

21 August 2017

volume

26

1 reference

21 August 2017

issue

12

1 reference

21 August 2017

page(s)

2543-2550

1 reference

Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report (Georgetown University, Washington, DC, May 29-30, 2002).

21 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11095-009-9990-3

Application of fixed exponent 0.75 to the prediction of human drug clearance: an inaccurate and misleading concept

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11095-009-9990-3

Interspecies scaling of clearance and volume of distribution for digoxin-specific Fab.

21 January 2018

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers.

1 reference

12 December 2020

Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor.

1 reference

12 December 2020

Dose-dependent pharmacokinetics of cyclosporin A in rats: events in tissues.

1 reference

12 December 2020

Antibody pharmacokinetics and pharmacodynamics

1 reference

12 December 2020

A physiologic model for simulating gastrointestinal flow and drug absorption in rats.

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjects.

1 reference

12 December 2020

Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice

1 reference

12 December 2020

Whole body physiologically-based pharmacokinetic models: their use in clinical drug development

1 reference

12 December 2020

A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn).

1 reference

12 December 2020

Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics.

1 reference

12 December 2020

An evaluation of the utility of physiologically based models of pharmacokinetics in early drug discovery.

1 reference

12 December 2020

Physiologically based pharmacokinetic modelling: a sub-compartmentalized model of tissue distribution.

1 reference

12 December 2020

Physiology-based pharmacokinetic modeling: ready to be used

1 reference

12 December 2020

Whole-body physiologically based pharmacokinetic models

1 reference

12 December 2020

Local kinetics and dynamics of xenobiotics

1 reference

12 December 2020

Physiologically based pharmacokinetic study on a cyclosporin derivative, SDZ IMM 125

1 reference

12 December 2020

Pharmacokinetic aspects of biotechnology products

1 reference

12 December 2020

Early development of therapeutic biologics--pharmacokinetics.

1 reference

12 December 2020

A compartmental absorption and transit model for estimating oral drug absorption.

1 reference

12 December 2020

Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice.

1 reference

12 December 2020

Pharmacokinetics of monoclonal immunoglobulin G1, F(ab')2, and Fab' in mice

1 reference

12 December 2020

From physicochemistry to absorption and distribution: predictive mechanistic modelling and computational tools

1 reference

12 December 2020

Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of humanized monoclonal anti-IL-13 antibodies with different IL-13 neutralization mechanisms

1 reference

12 December 2020

Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs.

1 reference

12 December 2020

Physiologically based pharmacokinetics of cyclosporine A: reevaluation of dose-nonlinear kinetics in rats.

1 reference

12 December 2020

Interspecies comparisons of pharmacokinetics and pharmacodynamics of recombinant human erythropoietin.

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic considerations in gene therapy

1 reference

12 December 2020

Application of full physiological models for pharmaceutical drug candidate selection and extrapolation of pharmacokinetics to man

1 reference

12 December 2020

Physiologically based pharmacokinetics of cyclosporine A: extension to tissue distribution kinetics in rats and scale-up to human

1 reference

12 December 2020

Physiological pharmacokinetic models: some aspects of theory, practice and potential

1 reference

12 December 2020

10.1007/S11095-009-9990-3

Identifiers

DOI

1 reference

21 August 2017

1 reference